Mirum Pharmaceuticals' (MIRM) CEO Chris Peetz on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/21
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire • 05/06/21
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million DealSeeking Alpha • 05/03/21
Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021Business Wire • 04/29/21
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver DiseasesBusiness Wire • 04/29/21
Mirum Pharmaceuticals Receives Notice of Allowance for Methods of Use Patent for Maralixibat in Alagille SyndromeBusiness Wire • 04/26/21
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet's Gene Therapy Programs Targeting Progressive Familial Intrahepatic CholestasisBusiness Wire • 04/12/21
Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille SyndromeBusiness Wire • 03/29/21
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/09/21
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business UpdatesBusiness Wire • 03/09/21
Mirum Pharmaceuticals Announces Completion of Rolling NDA Submission for Maralixibat in Alagille SyndromeBusiness Wire • 02/01/21
Mirum Pharmaceuticals Honors Alagille Syndrome Awareness Day with Launch of Disease Awareness CampaignBusiness Wire • 01/24/21
Mirum Pharmaceuticals Announces First Patient Enrolled in Phase 2b VISTAS Clinical Study Evaluating Volixibat in Adult Patients With Primary Sclerosing CholangitisBusiness Wire • 01/14/21
Mirum Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021Business Wire • 01/04/21
Mirum Pharmaceuticals and Oberland Capital Announce Up to $210 Million Funding ArrangementBusiness Wire • 12/09/20
Mirum Pharmaceuticals Announces European Medicines Agency Validation of the Marketing Authorization Application for Maralixibat in Patients with PFIC2Business Wire • 11/30/20
Mirum Pharmaceuticals Announces Data Presented During AASLD Highlighting Durable Improvements in Pruritus and Quality of Life in Children with Alagille Syndrome Treated with MaralixibatBusiness Wire • 11/15/20
Mirum Pharmaceuticals Presents New Data From Its Maralixibat and Volixibat Clinical Studies at AASLD Annual MeetingBusiness Wire • 11/13/20
Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor DayBusiness Wire • 11/12/20